WSD-0922, a novel brain-penetrant inhibitor of epidermal growth factor receptor, promotes survival in glioblastoma mouse models

BACKGROUND: Although the epidermal growth factor receptor (EGFR) is a frequent oncogenic driver in glioblastoma (GBM), efforts to therapeutically target this protein have been largely unsuccessful. The present preclinical study evaluated the novel EGFR inhibitor WSD-0922. METHODS: We employed flank...

Descripción completa

Detalles Bibliográficos
Autores principales: Conage-Pough, Jason E, Stopka, Sylwia A, Oh, Ju-Hee, Mladek, Ann C, Burgenske, Danielle M, Regan, Michael S, Baquer, Gerard, Decker, Paul A, Carlson, Brett L, Bakken, Katrina K, Zhang, Jinqiang, Liu, Lily, Sun, Claire, Mu, Zhihua, Zhong, Wei, Tran, Nhan L, Elmquist, William F, Agar, Nathalie Y R, Sarkaria, Jann N, White, Forest M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Basic and Translational Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263119/
https://www.ncbi.nlm.nih.gov/pubmed/37324218
http://dx.doi.org/10.1093/noajnl/vdad066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263119/
https://www.ncbi.nlm.nih.gov/pubmed/37324218
http://dx.doi.org/10.1093/noajnl/vdad066

Ejemplares similares